Altimmune (ALT) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
20.0K
Operating Income
-103.2M
-515,860.00%
Net Income
-95.1M
-475,295.00%
EPS (Diluted)
-$1.34
Balance Sheet Metrics
Total Assets
139.3M
Total Liabilities
15.8M
Shareholders Equity
123.5M
Debt to Equity
0.13
Cash Flow Metrics
Operating Cash Flow
-80.6M
Free Cash Flow
-79.8M
Revenue & Profitability Trend
Altimmune Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 20.0K | 426.0K | -68.0K | 4.4M | 8.2M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 103.2M | 83.9M | 87.7M | 90.0M | 63.0M |
| Operating Income | -103.2M | -83.5M | -87.7M | -85.5M | -54.8M |
| Pre-tax Income | -95.1M | -88.4M | -84.9M | -97.1M | -54.5M |
| Income Tax | - | 0 | -197.0K | 0 | -5.4M |
| Net Income | -95.1M | -88.4M | -84.7M | -97.1M | -49.0M |
| EPS (Diluted) | -$1.34 | -$1.66 | -$1.81 | -$2.35 | -$1.91 |
Income Statement Trend
Altimmune Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 137.3M | 209.6M | 192.8M | 204.1M | 230.3M |
| Non-Current Assets | 2.1M | 1.0M | 14.1M | 14.7M | 14.9M |
| Total Assets | 139.3M | 210.6M | 206.9M | 218.9M | 245.1M |
| Liabilities | |||||
| Current Liabilities | 10.5M | 12.1M | 17.1M | 18.3M | 12.0M |
| Non-Current Liabilities | 5.3M | 4.4M | 4.6M | 1.5M | 7.2M |
| Total Liabilities | 15.8M | 16.5M | 21.6M | 19.7M | 19.2M |
| Equity | |||||
| Total Shareholders Equity | 123.5M | 194.1M | 185.3M | 199.1M | 225.9M |
Balance Sheet Composition
Altimmune Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -95.1M | -88.4M | -84.7M | -97.1M | -49.0M |
| Operating Cash Flow | -80.6M | -82.4M | -70.0M | -82.4M | -39.9M |
| Investing Activities | |||||
| Capital Expenditures | 0 | -47.0K | -126.0K | -12.1M | -204.0K |
| Investing Cash Flow | -28.4M | 13.7M | -73.4M | 87.7M | -72.1M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 9.1M | 86.0M | 55.8M | 64.9M | 172.3M |
| Free Cash Flow | -79.8M | -75.9M | -62.7M | -90.6M | -34.6M |
Cash Flow Trend
Altimmune Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.18
Forward P/E
-2.90
Price to Book
2.33
Price to Sales
17,275.79
PEG Ratio
-2.90
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-436,300.00%
Return on Equity
-57.28%
Return on Assets
-35.51%
Financial Health
Current Ratio
15.85
Debt to Equity
1.12
Beta
0.58
Per Share Data
EPS (TTM)
-$1.26
Book Value per Share
$1.83
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| alt | 345.5M | -3.18 | 2.33 | -57.28% | 0.00% | 1.12 |
| Vertex | 120.4B | 32.82 | 7.30 | -5.64% | -8.91% | 10.00 |
| Regeneron | 61.3B | 14.43 | 2.05 | 15.96% | 31.94% | 9.20 |
| Disc Medicine | 2.0B | 4.99 | 3.02 | -23.34% | 0.00% | 4.64 |
| Cg Oncology | 2.0B | -18.06 | 2.80 | -16.58% | 0.00% | 0.15 |
| Ideaya Biosciences | 2.0B | - | 1.92 | -31.34% | 0.00% | 2.54 |
Financial data is updated regularly. All figures are in the company's reporting currency.